Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.07 USD
-0.46 (-4.37%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $10.08 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DVAX 10.07 -0.46(-4.37%)
Will DVAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
New Strong Sell Stocks for July 9th
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Other News for DVAX
Kelly MacDonald Returns as CFO to Dynavax Technologies
Dynavax re-appoints Kelly MacDonald as CFO
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024